Sg3 Management, LLC Fibrogen Inc Call Options Transaction History

Sg3 Management, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$7.94 - $12.96 $79,400 - $129,600	-10,000 Reduced 50.0%	10,000 $106,000
Q1 2022 May 16, 2022	SELL	$12.02 - $16.79 $60,100 - $83,950	-5,000 Reduced 20.0%	20,000 $240,000
Q4 2021 Feb 15, 2022	BUY	$9.93 - $15.39 $248,250 - $384,750	25,000 New	25,000 $353,000
Q3 2021 Nov 15, 2021	SELL	$10.18 - $26.64 $510,018 - $1.33 Million	-50,100 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$18.57 - $35.68 $94,707 - $181,968	5,100 Added 11.33%	50,100 $1.33 Million
Q1 2021 May 17, 2021	BUY	$31.0 - $55.72 $945,500 - $1.7 Million	30,500 Added 210.34%	45,000 $1.56 Million
Q4 2020 Feb 16, 2021	BUY	$37.09 - $48.97 $370,900 - $489,700	10,000 Added 222.22%	14,500 $538,000
Q3 2020 Nov 13, 2020	BUY	$40.47 - $45.5 $182,115 - $204,750	4,500 New	4,500 $185,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.